Indications and uses
Helps prevent sunburn
Helps prevent sunburn
For sunscreen use: Shake well before use. Apply liberally 15 minutes before sun exposure. Reapply at least every two hours. Use a water resistant sunscreen if swimming or sweating. Sun protection measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measure...
Titanium Dioxide 2.92 %
sunscreen
on damaged or broken skin.
if rash occurs.
If swallowed, get medical help or contact a Poison Control Center right away.
For sunscreen use:
AQUA (WATER) - METHYL TRIMETHICONE - DIMETHICONE - ISODODECANE - ALCOHOL - PEG-9 POLYDIMETHYLSILOXYETHYL DIMETHICONE - ACRYLATES/DIMETHICONE COPOLYMER - SILICA - BUTYLENE GLYCOL - MICA - ALUMINUM HYDROXIDE - PHENOXYETHANOL - PHENYL TRIMETHICONE - DISTEARDIMONIUM HECTORITE - SODIUM MYRISTOYL GLUTAMATE - STEARIC ACID -
GLYCERYL UNDECYL DIMETHICONE - VP/VA COPOLYMER - PROPYLENE CARBONATE - PARFUM (FRAGRANCE) - SODIUM CHLORIDE - TROMETHAMINE - BHT - BUTYLPHENYL
METHYLPROPIONAL - LINALOOL - CITRONELLOL - ALPHA-ISOMETHYL IONONE - BENZYL BENZOATE - GERANIOL - [MAY CONTAIN: CI 77891 (TITANIUM DIOXIDE) - CI 77492, CI 77491, CI 77499 (IRON OXIDES)]
In USA: 19 East, 57th Street, New York, NY 10022 (07856)
FOR WOMEN WHO PLACE ALLURE, ELEGANCE AND PERFECTION BEFORE ALL ELSE, GUERLAIN HAS CREATED TENUE DE PERFECTION. NO MERE FOUNDATION, IT IS A MULTISENSORY ELIXIR THAT ADAPTS TO EVERY SITUATION AND ENSURES A PERFECT COMPLEXION THAT REMAINS FLAWLESS EVEN AFTER THE STROKE OF MIDNIGHT.
THREE EPHEMERAL MULTISENSORY OILS FOR DIVINE RESULTS
A FIRST FOR GUERLAIN, THE FORMULA IS BASED ON THREE ESSENTIAL OILS THAT EVAPORATE ONE AFTER THE OTHER, WITH THREE SUCCESSIVE EFFECTS ON THE SKIN: - THE FIRST OIL, THE MOST FLEETING, EVAPORATES UNDER THE FINGERS TO ENSURE PERFECT WEAR FOR THE FOUNDATION, WHICH GENTLY MELTS INTO THE SKIN. - THE SECOND OIL COATS THE SKIN MORE COMPLETELY, ALLOWING THE FOUNDATION TO GLIDE ON AND ENSURING UNIFORM COVERAGE BEFORE VANISHING INTO THE SKIN.
- THE LAST OIL IS THEN RELEASED TO SETTLE AND FIX THE TIMEPROOF COMPLEX LIGHTLY ON THE SKIN ENSURING THAT THE FOUNDATION REMAINS IN PLACE FOR HOURS ON END.
ULTIMATE CORRECTION, ULTIMATE WEAR: THE TIMEPROOF COMPLEX
THE CULMINATION OF GUERLAIN'S EXPERTISE, THIS SOPHISTICATED TECHNOLOGY OF ABSORBENT POWDERS AND CORRECTIVE PIGMENTS SETS TO WORK INSTANTLY, TURNING THE TEXTURE OF THE SKIN VELVETY SOFT AND ENSURING FLAWLESS COVERAGE IN ALL SITUATIONS:
- FOR ULTIMATE CORRECTION, TWO SOFT-FOCUS MICRO-POWDERS PROVIDE COMPLEMENTARY PROPERTIES: THE FIRST, IN THE FORM OF FLECKS, ENVELOPS THE CONTOURS OF THE SKIN TO SMOOTH ITS SURFACE; THE SECOND'S SPHERICAL SHAPE "ROLLS" OVER THE SKIN TO SMOOTH OUT THE APPEARANCE OF FINE LINES AND SOFTEN IMPERFECTIONS.
- FOR IMPECCABLE WEAR, CONCENTRATED PIGMENTS AND ABSORBENT BEADS ARE ENCAPSULATED IN A POLYMER THAT ROLLS ONTO THE SKIN, FORMING A SUPPLE AND UNIFORM VEIL THAT HOLDS FOR HOURS ON END. BEADS OF SILICA FURTHER THE EFFECT BY CAPTURING ANY EXCESS SEBUM, KEEPING THE VEIL INTACT, WHILE THE SPHERICAL MICRO-POWDER HELPS STABLISE THE COLOUR, ENSURING THAT IT DOES NOT CHANGE OR DARKEN.
THE ULTIMATE BEAUTY OF SMOOTH, EVEN-TONED, VELVETY SKIN IS INSTANTLY REVEALED.
INTO THE EVENING AND BEYOND, THE COMPLEXION STAYS IMPECCABLY FRESH AND VIBRANT, AS PERFECT AS WHEN IT WAS FIRST APPLIED.
16-HOUR HOLD REPORTED BY 93% OF WOMEN*
ALL-DAY COMFORT: 90%**
PERFECTLY CORRECTED COMPLEXION: 83%**
* SELF EVALUATION BY 15 WOMEN, AFTER DAILY APPLICATION.
** SATISFACTION TEST INCLUDING 30 WOMEN, IMMEDIATE RESULTS AND AFTER FOUR WEEKS OF DAILY APPLICATION.
© COPYRIGHT GUERLAIN
68, CHAMPS-ELYSEES 75008 PARIS
MADE IN FRANCE
www.guerlain.com 9 M
04 BEIGE MOYEN
3 346470 416918
REPIQUAGE USINE
GUERLAIN TENUE DE PERFECTION TIMEPROOF FOUNDATION WITH SUNSCREEN ULTIMATE LASTING PERFECTION BROAD SPECTRUM SPF 20 04 BEIGE MOYEN 30ml e 1 FL OZ
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| TITANIUM DIOXIDE | ACTIVE INGREDIENT | 15FIX9V2JP | 5 | |
| TITANIUM DIOXIDE | ACTIVE MOIETY | 15FIX9V2JP | 5 | |
| .BETA.-CITRONELLOL, (R)- | INACTIVE INGREDIENT | P01OUT964K | 5 | |
| ALCOHOL | INACTIVE INGREDIENT | 3K9958V90M | 5 | |
| ALUMINUM HYDROXIDE | INACTIVE INGREDIENT | 5QB0T2IUN0 | 5 | |
| BENZYL BENZOATE | INACTIVE INGREDIENT | N863NB338G | 5 | |
| BUTYLATED HYDROXYTOLUENE | INACTIVE INGREDIENT | 1P9D0Z171K | 5 | |
| BUTYLPHENYL METHYLPROPIONAL | INACTIVE INGREDIENT | T7540GJV69 | 5 | |
| COPOVIDONE K25-31 | INACTIVE INGREDIENT | D9C330MD8B | 5 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 5 | |
| DISTEARDIMONIUM HECTORITE | INACTIVE INGREDIENT | X687XDK09L | 5 | |
| FERRIC OXIDE RED | INACTIVE INGREDIENT | 1K09F3G675 | 5 | |
| FERRIC OXIDE YELLOW | INACTIVE INGREDIENT | EX438O2MRT | 5 | |
| FERROSOFERRIC OXIDE | INACTIVE INGREDIENT | XM0M87F357 | 5 | |
| GERANIOL | INACTIVE INGREDIENT | L837108USY | 5 | |
| ISODODECANE | INACTIVE INGREDIENT | A8289P68Y2 | 5 | |
| ISOMETHYL-.ALPHA.-IONONE | INACTIVE INGREDIENT | 9XP4LC555B | 5 | |
| LINALOOL, (+/-)- | INACTIVE INGREDIENT | D81QY6I88E | 5 | |
| METHYL TRIMETHICONE | INACTIVE INGREDIENT | S73ZQI0GXM | 5 | |
| MICA | INACTIVE INGREDIENT | V8A1AW0880 | 5 | |
| PEG-9 POLYDIMETHYLSILOXYETHYL DIMETHICONE | INACTIVE INGREDIENT | TYP81E471F | 5 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 5 | |
| PHENYL TRIMETHICONE | INACTIVE INGREDIENT | DR0K5NOJ4R | 5 | |
| PROPYLENE CARBONATE | INACTIVE INGREDIENT | 8D08K3S51E | 5 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 5 | |
| SODIUM CHLORIDE | INACTIVE INGREDIENT | 451W47IQ8X | 5 | |
| SODIUM MYRISTOYL GLUTAMATE | INACTIVE INGREDIENT | AYU7QD893W | 5 | |
| STEARIC ACID | INACTIVE INGREDIENT | 4ELV7Z65AP | 5 | |
| TROMETHAMINE | INACTIVE INGREDIENT | 023C2WHX2V | 5 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 5 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 49817-0070 | 49817-0070-1, 49817-0070-2 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| ALUMINUM HYDROXIDE | ALUMINUM HYDROXIDE | 5QB0T2IUN0 | CAPSULE / ORAL | NA | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | TABLET, CHEWABLE / ORAL | 14 mg | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, COATED / ORAL | 42.4 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | LIQUID / RESPIRATORY (INHALATION) | 5 %w/w | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | INJECTION, SOLUTION / INTRA-ARTERIAL | 300 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | POWDER, FOR SOLUTION / TOPICAL | 40 %w/w | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | DROPS / NASAL | 10 mg/1ml | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | IMPLANT / SUBCUTANEOUS | 77 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRATUMOR | 1.2 %w/v | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | GEL / TOPICAL | 14 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / NASAL | 10 mg/1ml | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION / ORAL | 1.21 mg/1ml | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRACAUDAL | 210 mg | ||
| FERRIC OXIDE YELLOW | FERRIC OXIDE YELLOW | EX438O2MRT | GRANULE, FOR SUSPENSION / ORAL | 11 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET, FILM COATED / ORAL | 5917 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | DROPS / ORAL | 210 mg/1ml | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, FOAM / TOPICAL | 4504 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SOLUTION / INTRATHECAL | 1.35 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | CAPSULE / ORAL | 6 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / SUBMUCOSAL | 17 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / PERINEURAL | 648 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | CREAM / TOPICAL | 6 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SPRAY / SUBLINGUAL | 397 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SOLUTION / TRANSDERMAL | 49.37 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER, FOR SUSPENSION / ORAL | 98 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / RESPIRATORY (INHALATION) | 43 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | AEROSOL, METERED / RESPIRATORY (INHALATION) | 26664 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / NASAL | 330 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | POWDER, FOR SUSPENSION / ORAL | 1 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | POWDER / RESPIRATORY (INHALATION) | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, CHEWABLE / ORAL | 254 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET / ORAL | 231 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | AEROSOL, FOAM / TOPICAL | 4 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | POWDER, FOR SUSPENSION / ORAL | 5917 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / OPHTHALMIC | 13 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SPRAY / NASAL | 30 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION / INTRATHECAL | 0.12 %w/v | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | POWDER, FOR SUSPENSION / ORAL | 1203 mg/5ml | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | TABLET, FILM COATED / ORAL | 176 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | TABLET, CHEWABLE / ORAL | 20 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SUSPENSION / ENDOTRACHEAL | 7.6 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRASYNOVIAL | 0.9 %w/v | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CREAM / VAGINAL | 51 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / DENTAL | 19 %w/w | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / RESPIRATORY (INHALATION) | NA | ||
| STEARIC ACID | STEARIC ACID | 4ELV7Z65AP | LOTION / TOPICAL | 80 mg | ||
| ALCOHOL | ALCOHOL | 3K9958V90M | SUSPENSION / RECTAL | 0.35 %v/v | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, EXTENDED RELEASE / ORAL | 168 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 336 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, SUSPENSION / INTRAVITREAL | 6 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION, POWDER, FOR SUSPENSION / SUBCUTANEOUS | NA | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | SOLUTION, GEL FORMING / DROPS / OPHTHALMIC | 1 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE, COATED PELLETS / ORAL | 2 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET, ORALLY DISINTEGRATING / ORAL | 2 mg | ||
| BUTYLATED HYDROXYTOLUENE | BUTYLATED HYDROXYTOLUENE | 1P9D0Z171K | SOLUTION / ORAL | 14 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, DELAYED RELEASE / ORAL | 3.2 mg | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | SOLUTION / EPIDURAL | 0.9 %w/v | ||
| SODIUM CHLORIDE | SODIUM CHLORIDE | 451W47IQ8X | INJECTION / INTRA-ARTERIAL | 278 mg | ||
| TROMETHAMINE | TROMETHAMINE | 023C2WHX2V | CAPSULE / ORAL | 30 mg | ||
| COPOVIDONE K25-31 | COPOVIDONE K25-31 | D9C330MD8B | TABLET, CHEWABLE / ORAL | 5 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| ed169a96-8447-2ac4-e053-2995a90a986d | 87abd139-cfba-4c19-82e9-7db0e282c0d6 | 2022-11-09 | Warnings | 87abd139-cfba-4c19-82e9-7db0e282c0d6 |
Adverse event summaries are temporarily unavailable. Other product information remains available.